ADULT AIDS CLINICAL TRIALS UNIT

成人艾滋病临床试验单位

• 批准号: 3547373
• 负责人: RONALD T. MITSUYASU
• 金额: $ 204.66万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-06-30 至 1995-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3547373
• 关键词: AIDS; AIDS therapy; HIV infections; clinical trials; cooperative study; human subject; human therapy evaluation

UCLA AIDS Clinical Trials Univ (ACTU) has been a very active participant in the scientific and clinical activities of the ACTG since its inception in 1986. The clinical component of the UCLA ACTU consists of the main unit at the UCLA Center for the Health Sciences and subunit sites at Harbor-UCLA Medical Center, the UCLA-San Fernando Valley program (Olive View Medical Center and Sepulveda VA Hospital). This consortium of UCLA academically affiliated hospitals provides differing expertise as well as access to geographically dispersed and racial/ethnically diverse populations of HIV- infected Los Angeles residents. UCLA main site will accrue to high priority Phase II/III antiretroviral studies but will also emphasize high priority Phase I and Phase II trials of antiretroviral drugs, immune based therapies, and therapies for AIDS-related malignancies. Harbor-UCLA and the hospitals of the UCLA-San Fernando Valley program (UCLA/SFVP) will focus primarily on Phase II and Phase III trials of antiretroviral drugs and treatments for opportunistic infections. The accrual of minority men an women will be facilitated by continuing our productive subunits at 2 LA County Public Hospitals, Harbor-UCLA Medical Center and Olive View Medical Center which are located in geographically distinct areas of LA County. Substance abusers and minorities will also be accused at the VA hospital which runs a large drug abuse treatment clinic. More women will be enrolled through greater outreach efforts for an HIV women's clinic at the UCLA main site and by coordination with the Pediatric ACTU at UCLA through its Maternal Child Family HIV Clinic both of which will operate in our soon-to-open HIV outpatient clinic facility. UCLA investigators will continue to serve in leadership capacities within the ACTG research and resource committees, and we anticipate even greater scientific involvement as new investigators become involved from UCLA and its subunits. Our core laboratories in immunology, virology, and pharmacology have been consistently certified and highly rated in quality assurance evaluations and will continue to be involved in clinical trials support activity of the ACTG (C.1,C.2). Immunology developmental research (C5). headed by John Fahey will evaluate surrogate serum and cellular phenotypic markers of immunodeficiency or immune activation in relation to clinical or immunologic efficacy of new antiviral or immune based therapies.

加州大学洛杉矶分校艾滋病临床试验大学 (ACTU) 一直是非常积极的参与者 ACTG 自成立以来的科学和临床活动 1986. 加州大学洛杉矶分校 ACTU 的临床部分由主要单位组成 加州大学洛杉矶分校健康科学中心和加州大学洛杉矶分校港口分校的亚单位站点 医疗中心，加州大学洛杉矶分校-圣费尔南多谷项目 (Olive View Medical 中心和 Sepulveda VA 医院）。 加州大学洛杉矶分校的这个学术联盟 附属医院提供不同的专业知识以及获取信息的机会 地理上分散且具有不同种族/族裔的艾滋病毒感染者群体 感染了洛杉矶居民。 加州大学洛杉矶分校主站将累积至高 优先考虑 II/III 期抗逆转录病毒研究，但也将强调高 优先进行基于免疫的抗逆转录病毒药物的 I 期和 II 期试验 疗法，以及艾滋病相关恶性肿瘤的疗法。 港口-加州大学洛杉矶分校和 加州大学洛杉矶分校-圣费尔南多谷项目 (UCLA/SFVP) 的医院将 主要关注抗逆转录病毒药物的 II 期和 III 期试验 以及机会性感染的治疗。 少数族裔男性的收益 继续我们在 2 LA 的生产性子单位的工作，将为女性提供便利 县公立医院、Harbor-UCLA 医疗中心和 Olive View Medical 中心位于洛杉矶县的不同地理区域。 药物滥用者和少数族裔也将在退伍军人管理局医院受到指控 经营一家大型药物滥用治疗诊所。 将会有更多的女性 通过加大艾滋病毒妇女诊所的外展力度而入组 加州大学洛杉矶分校主站点，并通过与加州大学洛杉矶分校儿科 ACTU 协调 其母婴家庭艾滋病毒诊所均将在我们的诊所运营 即将开放的艾滋病毒门诊设施。 加州大学洛杉矶分校的调查人员将 继续在 ACTG 研究领域发挥领导作用 资源委员会，我们预计会有更多的科学参与 随着加州大学洛杉矶分校及其下属单位的新调查人员参与其中。 我们的核心 免疫学、病毒学和药理学实验室 在质量保证评估中获得一致认证和高度评价 并将继续参与临床试验支持活动 ACTG（C.1，C.2）。 免疫学发展研究（C5）。以约翰为首 Fahey 将评估替代血清和细胞表型标记 与临床或相关的免疫缺陷或免疫激活 新的抗病毒或基于免疫的疗法的免疫功效。